Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Functional neurological disorders after COVID-19 and SARS-CoV-2 vaccines: a national multicentre observational study.
Alonso-Canovas A, Kurtis MM, Gomez-Mayordomo V, Macías-García D, Gutiérrez Viedma Á, Mondragón Rezola E, Pagonabarraga J, Aranzabal Orgaz L, Masjuan J, Martinez-Castrillo JC, Pareés I. Alonso-Canovas A, et al. Among authors: masjuan j. J Neurol Neurosurg Psychiatry. 2023 Sep;94(9):776-777. doi: 10.1136/jnnp-2022-330885. Epub 2023 Mar 8. J Neurol Neurosurg Psychiatry. 2023. PMID: 36889911 No abstract available.
COVID-19 vaccines are not associated with axonal injury in patients with multiple sclerosis.
Sainz de la Maza S, Rodero-Romero A, Monreal E, Chico-García JL, Villarrubia N, Rodríguez-Jorge F, Fernández-Velasco JI, Sainz-Amo R, Costa-Frossard L, Masjuan J, Villar LM. Sainz de la Maza S, et al. Among authors: masjuan j. Front Immunol. 2024 Aug 22;15:1439393. doi: 10.3389/fimmu.2024.1439393. eCollection 2024. Front Immunol. 2024. PMID: 39238642 Free PMC article.
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.
Monreal E, Fernández-Velasco JI, García-Sánchez MI, Sainz de la Maza S, Llufriu S, Álvarez-Lafuente R, Casanova B, Comabella M, Ramió-Torrentà L, Martínez-Rodríguez JE, Brieva L, Saiz A, Eichau S, Cabrera-Maqueda JM, Villarrubia N, Espiño M, Pérez-Miralles F, Montalbán X, Tintoré M, Quiroga-Varela A, Domínguez-Mozo MI, Rodríguez-Jorge F, Chico-García JL, Lourido D, Álvarez-Cermeño JC, Masjuan J, Costa-Frossard L, Villar LM. Monreal E, et al. Among authors: masjuan j. JAMA Neurol. 2023 Apr 1;80(4):397-403. doi: 10.1001/jamaneurol.2023.0010. JAMA Neurol. 2023. PMID: 36848127 Free PMC article.
Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine.
Rodero-Romero A, Sainz de la Maza S, Fernández-Velasco JI, Monreal E, Walo-Delgado PE, Chico-García JL, Villarrubia N, Rodríguez-Jorge F, Rodríguez-Ramos R, Masjuan J, Costa-Frossard L, Villar LM. Rodero-Romero A, et al. Among authors: masjuan j. Vaccines (Basel). 2023 Aug 22;11(9):1399. doi: 10.3390/vaccines11091399. Vaccines (Basel). 2023. PMID: 37766078 Free PMC article.
Establishing the best combination of the kappa free light chain index and oligoclonal bands for an accurate diagnosis of multiple sclerosis.
Monreal E, Fernández-Velasco JI, García-Soidán A, Sainz de la Maza S, Espiño M, Villarrubia N, Rodríguez-Jorge F, Chico-García JL, Sainz-Amo R, Masjuan J, Costa-Frossard L, Villar LM. Monreal E, et al. Among authors: masjuan j. Front Immunol. 2023 Oct 25;14:1288169. doi: 10.3389/fimmu.2023.1288169. eCollection 2023. Front Immunol. 2023. PMID: 37954589 Free PMC article.
Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.
Sainz-Amo R, Rodero Romero A, Monreal E, Chico García JL, Fernández Velasco JI, Villarrubia N, Veiga González JL, Sainz de la Maza S, Rodríguez Jorge F, Masjuan J, Costa-Frossard L, Villar LM. Sainz-Amo R, et al. Among authors: masjuan j. Front Immunol. 2024 Aug 19;15:1454474. doi: 10.3389/fimmu.2024.1454474. eCollection 2024. Front Immunol. 2024. PMID: 39224593 Free PMC article.
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry.
Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V, Sanmartin Fernández M, Arribas F, Masjuan J, Barrios V, Cosin-Sales J, Freixa-Pamias R, Recalde E, Pérez-Cabeza AI, Manuel Vázquez Rodríguez J, Ràfols Priu C, Anguita Sánchez M, Lip GYH, Marin F. Esteve-Pastor MA, et al. Among authors: masjuan j. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):38-46. doi: 10.1093/ehjcvp/pvac060. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 36318457
209 results